Dignitana applies for delisting
10 juni, 09:40
Dignitana applies for delisting
The outcome of the extended acceptance period in the public takeover offer from Paxman AB (publ) (“Paxman”) regarding Dignitana AB (“Dignitana”) was announced by Paxman on 2 June 2025. Paxman controls more than 90 percent of the shares and votes in Dignitana and has initiated a compulsory acquisition procedure in respect of the remaining shares in Dignitana.
The board of directors of Dignitana has, at the request of Paxman, today resolved to apply for delisting of Dignitana’s shares from Nasdaq First North Growth Market. The last day of trading in Dignitana’s shares on Nasdaq First North Growth Market will be announced as soon as Dignitana has received confirmation of such date from Nasdaq.
About Dignitana
Dignitana AB is a Swedish medical technology company specializing in scalp cooling. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
Ämnen i artikeln
Dignitana applies for delisting
10 juni, 09:40
Dignitana applies for delisting
The outcome of the extended acceptance period in the public takeover offer from Paxman AB (publ) (“Paxman”) regarding Dignitana AB (“Dignitana”) was announced by Paxman on 2 June 2025. Paxman controls more than 90 percent of the shares and votes in Dignitana and has initiated a compulsory acquisition procedure in respect of the remaining shares in Dignitana.
The board of directors of Dignitana has, at the request of Paxman, today resolved to apply for delisting of Dignitana’s shares from Nasdaq First North Growth Market. The last day of trading in Dignitana’s shares on Nasdaq First North Growth Market will be announced as soon as Dignitana has received confirmation of such date from Nasdaq.
About Dignitana
Dignitana AB is a Swedish medical technology company specializing in scalp cooling. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
Ämnen i artikeln
Analyser
-992x558.webp&w=3840&q=75)
AI-boomen
.jpg&w=3840&q=75)
Rapportsäsongen
Analyser
AI-boomen
Mest läst
Rapportsäsongen
Senaste nytt
Marknadsöversikt
OMX Stockholm 30
1 DAG %
0,98%
Senast
2 759,94
1 mån
Loading market data...
-950x950.webp&w=3840&q=75)
